



PTO/SB/08B

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for Form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	1	of	1	Attorney Docket Number	017620-9335
-------	---	----	---	------------------------	-------------

Complete if Known

Application Number	09/995,911
Filing Date	November 28, 2001
First Named Inventor	Richard B. Mazess
Group Art Unit	1617
Examiner Name	Theodore Criares
Attorney Docket Number	017620-9335

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
----------------------	--

<i>Lu</i>	Beer et al., "Rationale for the Development and Current Status of Calcitriol in Androgen-Independent Prostate Cancer," <i>World. J. Urol.</i> , (2004) 23:28-32.
<i>Lu</i>	Beer et al., "Randomized Study of High-Dose Pulse Calcitriol or Placebo Prior to Radical Prostatectomy," <i>Cancer Epidemiology</i> , (2004) 13:12:2225-2232.
<i>Lu</i>	Beer et al., "High-Dose Calcitriol and Carboplatin in Metastatic Androgen-Independent Prostate Cancer," <i>Amer. J. Clinical Oncology</i> , (2004) 27:5:535-541.
<i>Lu</i>	Beer et al., "Weekly Docetaxel in Elderly Patients with Prostate Cancer: Efficacy and Toxicity in Patients at Least 70 Years of Age Compared with Patients Younger than 70 Years," <i>Clinical Prostate Cancer</i> , (2003) 167-172.
<i>Lu</i>	Beer et al., "Calcitriol in Cancer Treatment: From the Lab to the Clinic," <i>Molecular Cancer Therapeutics</i> , (2004) 3:3:373-381.
<i>Lu</i>	Beer et al., "Quality of Life and Pain Relief During Treatment with Calcitriol and Docetaxel in Symptomatic Metastatic Androgen-Independent Prostate Carcinoma," <i>Cancer</i> , (2004) 758-763.
<i>Lu</i>	Beer T.M., "Development of Weekly High-Dose Calcitriol Based Therapy for Prostate Cancer," <i>Urologic Oncology</i> , (2003) 21:399-405.
<i>Lu</i>	Beer et al., "Docetaxel (Taxotere) in the Treatment of Prostate Cancer," <i>Future Drugs Ltd.</i> , (2003) 3:3:261-268.
<i>Lu</i>	Beer et al., "High-Dose Weekly Oral Calcitriol in Patients with a Rising PSA After Prostatectomy or Radiation for Prostate Carcinoma," <i>Cancer</i> , (2003) 97:5:1217-1224.
<i>Lu</i>	Beer et al., "Phase II Study of Weekly Docetaxel in Symptomatic Androgen-Independent Prostate Cancer," <i>Annals of Oncology</i> , (2001) 12:1273-1279.
<i>Lu</i>	Beer et al., "A Phase I Trial of Pulse Calcitriol in Patients with Refractory Malignancies," <i>Cancer</i> , (2001) 91:12:2431-2439.

U:\B0253084.1

Examiner Signature	<i>J. M. Wille</i>	Date Considered	<i>06/12/2005</i>
-----------------------	--------------------	--------------------	-------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.